Exceptional early blood pressure control rates: The ACCOMPLISH trial

References

• Zhang X., Xu X., Nasjletti A., Hintze T. H. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin‐mediated mechanism in canine coronary microvessels. J Cardiovasc Pharm 2000; 35: 195–202
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Bakris G. L., Wun C. C., Dahlof B., Lefkowitz M., Manfreda S., et al. Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial. Am J Hypertens 2004; 17: 793–801
   PubMed Web of Science ®Google Scholar
• Weber M. A., Bakris G. L., Dahlöf B., Pitt B., Velazquez E., Gupte J., et al. Baseline characteristics in the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. 2006 (in press), Blood Pressure
   Google Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman C., Green L. A., Izzo J. L., et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC7 Report. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Nwose O., Jean‐Louis L., Schofield L., Purkayastha D., Baron M. Initial angiotensin‐converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17: 495–501
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997
   PubMed Web of Science ®Google Scholar
• Weber M. A. The ALLHAT Report: A case of information and misinformation. J Clin Hypertens 2003; 5: 9–13
   Google Scholar
• Julius S., Kjeldsen S., Weber M., Brunner H. R., Ekman S., Hansson L., et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004; 363: 2022–2031
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011–1054
   Google Scholar
• Burt V. L., Whelton P., Roccella E. J., Brown C., Cutler J. A., Higgins M., et al. Prevalence of hypertension in the US adult population; Results from the Third National Health and Nutrition Examination Survey. Hypertension 1995; 25: 305–313
   PubMed Web of Science ®Google Scholar
• Neutel J. M., Smith D. H. G., Weber M. A. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17: 37–42
   PubMed Web of Science ®Google Scholar
• White W. B., Giles T. D., Bakris G. L., Neutel J. M., Davidai G., Weber M. A. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 2006; 151: 176–184
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): A multicentre randomized controlled trial. Lancet 2005; 366: 895–906
   PubMed Web of Science ®Google Scholar
• Poulter N. R., Wedel H., Dahlöf B., Sever P. S., Beevers D. G., Caulfield M., et al. for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA). Lancet 2005; 366: 907–913
   PubMed Web of Science ®Google Scholar
• Hansson L., Zanchetti A., Carruthers S. G., Dahlof B., Elmfeldt D., Julius S., et al. for the HOT Study Group. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762
   PubMed Web of Science ®Google Scholar
• Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Nikalson A., et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin‐converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611–616
   PubMed Web of Science ®Google Scholar
• Hansson L., Lindholm L. H., Ekbom T., Dahlof B., Lanke J., Schersten B., et al. for the STOP‐Hypertension‐2 study group. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity, the Swedish Trial in Old Patients with Hypertension‐2 study. Lancet 1999; 354: 1751–1756
   PubMed Web of Science ®Google Scholar
• Hansson L., Hedner T. M., Lund‐Johansen P., Kjeldsen S. E., Lindholm L. H., Syvertsen J. O., et al. for the NORDIL Study Group. Randomized trial effects of calcium antagonists compared with diuretics and (‐blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365
   PubMed Web of Science ®Google Scholar
• Brown M. J., Palmer C. R., Castaigne A., de Leeuw P. W., Mancia G., Rosenthal T., et al. Morbidity and mortality in patients randomized to double‐blind treatment with a long‐acting calcium‐channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372
   PubMed Web of Science ®Google Scholar
• Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995–1003
   PubMed Web of Science ®Google Scholar
• Cushman W. C., Ford C. E., Cutler J. A., Margolis K. L., Davis B. R., Grimm R. H., et al. for the ALLHAT Research Group. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404
   PubMedGoogle Scholar
• Weber M. A., Julius S., Kjeldsen S. E., Brunner H. R., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363: 2049–2051
   PubMed Web of Science ®Google Scholar
• Sever P. S., Dahlöf B., Poulter N. R., Wedel H., Beevers G., Caulfield M., et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‐than‐average cholesterol concentrations, in the Angio‐Scandinavian Cardiac Outcomes Trial–Lipid lowering Arm (ASCOT‐LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158
   PubMed Web of Science ®Google Scholar